Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
multiple biotech firms
|
| gptkbp:awards |
various industry awards
|
| gptkbp:businessModel |
focused on partnerships
|
| gptkbp:CEO |
Kai_Pinkernell
|
| gptkbp:clinicalTrials |
ongoing
solid tumors published in peer-reviewed journals various sites globally multiple phases of trials Phase I, II, and III aims for improved patient outcomes multiple innovative platforms |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:communityEngagement |
participates in health initiatives
|
| gptkbp:communityPartnerships |
with leading hospitals
|
| gptkbp:employees |
over 100
|
| gptkbp:financialPerformance |
monitored regularly
manages IP portfolio |
| gptkbp:financials |
annual reports available
|
| gptkbp:focus |
immunotherapy
|
| gptkbp:founded |
1997
|
| gptkbp:futurePlans |
expand into new markets
|
| gptkbp:globalPresence |
operates internationally
|
| gptkbp:hasPrograms |
composed of industry experts
|
| gptkbp:hasResearchInterest |
conducts market analysis
|
| gptkbp:headquarters |
gptkb:Martinsried,_Germany
|
| gptkbp:healthcare |
prioritizes patient safety in trials
involves patients in trials |
| gptkbp:historicalResearch |
international research projects
conducts extensive research. |
| https://www.w3.org/2000/01/rdf-schema#label |
Medigene Inc.
|
| gptkbp:investmentFocus |
available online
R&D initiatives dedicated section on website institutional and private investors |
| gptkbp:leadership |
experienced professionals
|
| gptkbp:market |
global market
analyzes industry trends approximately 200 million EUR |
| gptkbp:marketingStrategy |
focus on innovation
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:patentCitation |
numerous granted patents
|
| gptkbp:products |
T cell therapies
ongoing for new therapies |
| gptkbp:regulatoryCompliance |
various stages
adheres to regulations |
| gptkbp:research |
secured from various sources
|
| gptkbp:research_areas |
oncology
drives research initiatives |
| gptkbp:researchAndDevelopment |
active member of biotech community
|
| gptkbp:researchAreas |
cancer treatment
|
| gptkbp:researchInterest |
with other biotech firms
numerous publications in journals |
| gptkbp:stockSymbol |
MDG1
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:subsidiary |
gptkb:Medigene_AG
|
| gptkbp:sustainabilityPractices |
committed to sustainable practices
|
| gptkbp:technology |
collaborates with universities
T cell receptor technology licenses technology to partners |
| gptkbp:tradedOn |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:tributaryOf |
multiple candidates in development
|
| gptkbp:website |
www.medigene.de
|